Semax Nasal Kit: Intranasal Delivery of a Research Heptapeptide

The Semax Nasal Kit pairs research-grade Semax peptide with a delivery system formatted for intranasal administration in animal and tissue models. Semax itself is a heptapeptide derived from the N-terminal region of adrenocorticotropic hormone (ACTH 4–10), modified for stability against enzymatic degradation. The nasal-spray format is of particular interest to investigators studying the nose-to-brain delivery route for centrally acting peptides.

Note: All content on this page is intended strictly for research and educational purposes. Semax is a research compound and is not approved for human use by the FDA or any regulatory authority.

Why Intranasal Delivery Is Studied

The nasal cavity has been a long-running area of interest in central nervous system pharmacology because it offers a route that, in animal models, has been shown to bypass first-pass hepatic metabolism and — via the olfactory and trigeminal nerve pathways — deliver a fraction of an administered compound directly into the cerebrospinal fluid and brain parenchyma. For small peptides like Semax, which are otherwise rapidly degraded in plasma, intranasal formats have been used as a research tool to study brain-region exposure, behavioral correlates, and time-course pharmacology in rodents and other model organisms.

The kit format provides a controllable, repeatable way for laboratories to administer Semax in volumes and concentrations relevant to nose-to-brain transport studies, rather than relying on parenteral injection in models where that route is undesirable or where comparing delivery routes is part of the experimental design.

Semax: A Brief Background

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) was developed at the Russian Academy of Sciences in the 1980s and 1990s as a research analog of ACTH 4–10, the heptapeptide fragment of adrenocorticotropic hormone with documented neurotropic properties but very short plasma half-life. The terminal Pro-Gly-Pro extension was introduced to slow enzymatic cleavage, yielding a peptide with extended in vivo activity in animal models. Decades of preclinical literature have accumulated around Semax, particularly from Russian and Eastern European research groups.

Proposed Mechanisms of Action

Preclinical studies have explored several mechanisms by which Semax may exert its observed neuroactive effects in cell and animal models:

• BDNF and NGF modulation: Multiple animal studies have reported increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue following Semax administration.
• Melanocortin and opioid receptor interactions: As an ACTH-derived peptide, Semax has been examined for non-classical interactions with melanocortin pathways, alongside reports of indirect modulation of endogenous opioid systems.
• Antioxidant and neuroprotective signaling: Rodent ischemia models have documented reductions in oxidative stress markers and infarct volume following Semax exposure, prompting interest in its neuroprotective mechanisms.
• Cognitive and attention-related behavioral endpoints: Animal-model behavioral assays have explored Semax’s effects on memory, attention, and stress-related behaviors, though translation to humans remains an open research question.

Research Applications for the Nasal Format

The intranasal kit format is especially useful for laboratories investigating:

• Nose-to-brain delivery pharmacology: Comparing CNS exposure of Semax via intranasal versus parenteral routes in rodent models.
• Behavioral pharmacology studies: Models examining attention, cognition, and stress response where repeated, low-volume dosing is needed.
• Ischemic and neuroprotection models: Stroke and oxidative stress models in which Semax has historically been administered intranasally in published rodent literature.
• Comparative bioavailability research: Studies that quantify peptide concentration in plasma, CSF, and brain tissue across delivery routes.

Handling and Storage

Lyophilized Semax is typically stored at -20°C or colder, protected from light and moisture. Once reconstituted in a sterile peptide-grade vehicle and dispensed into the nasal applicator, working solutions are commonly held at 2–8°C and used within a protocol-defined window. Avoid repeated freeze/thaw cycles. Investigators should confirm the chosen vehicle’s compatibility with their intended assay system and review nasal-formulation handling considerations specific to their animal-model protocol before use.

Why Investigators Choose the Kit Format

For research groups already working with Semax, the kit format reduces handling steps for nasal-delivery experiments and provides a more consistent administered volume across replicates. It also enables studies that compare delivery routes within a single experimental design without requiring separate sourcing or formulation steps for each arm.

Regulatory and Research-Use Status

Semax is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any condition in humans. The Semax Nasal Kit is offered strictly as a research-grade compound and delivery format for laboratory investigation. Material provided by Avenio Bio is intended only for qualified researchers working within institutional safety, ethics, and regulatory frameworks. See our Semax Nasal Kit product page for material specifications and lab handling notes, and the Semax research overview for broader background on the peptide’s pharmacology.

Disclaimer: This article is for informational and educational use within a research context. Avenio Bio products are intended strictly for laboratory and research purposes. Not for human consumption.